EORTC-30072-GUCG

A Phase III Randomised Double-blind Study Comparing Sorafenib With Placebo In Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse
Study documentation
Trial StatusClosed for recruitment
DatesDate of activation: 23-Mar-09
Closed on : 12-Apr-13
Data management at EORTCMailbox
Phase3
Randomized trialYes
TypeAdjuvant
Targeted Sample sizeEORTC Groups: 200 - All Groups: 1656
Number of steps1
DrugSorafenib
Study StaffSteven Joniau
Study Coordinator - U.Z. Leuven - Campus Gasthuisberg, Leuven
Richard Sylvester
Statistician - EORTC Headquarters, Brussels
Maarten De Rouck
Data Manager - EORTC Headquarters, Brussels
maarten.derouck (at) eortc.be - +32 27741660
Sandrine Marreaud
Coordinating Physician - EORTC Headquarters, Brussels
Julie Hermans
Project Manager - EORTC Headquarters, Brussels
julie.hermans (at) eortc.be - +32 27741673
Type of cancerKidney
Participating GroupsUniversity College of London(Coordinating Group)
EORTC Genito-Urinary Cancers Group
Protocol summaryClinicalTrials.gov
NCT numberNCT00492258
EudraCT2006-006079-19